日本语
 
http://www.superganoderma.com/
 
News
Xianzhilou Once Again invited to North America Promotion Conference
Xianzhilou Makes Big Success in the North America Promotion Conference
Save Green for the Next Generation,Xianzhilou Environment-Protecting Tree Planting Activity
More Love, More Hope --Xianzhilou and Organo Gold Charity Activity
West Strait Organic Ganoderma Industrial Park in Nanping
Xianzhilou invested hundreds of millions to establish GanoHerb Industrial Park in August,2009
Xianzhilou Company  is appointed to publish the national standard of Ganoderma lucidum spore powder
Xianzhilou organic Ganoderma products passed OK Kosher Certification
Season
XianzhiLou
Oct. 28,The leadership of the ministry of agriculture visited Xianzhilou giving a high appreciation
Embassy Papua New Guinea to China visit Fujian Xianzhilou
August 14th 2008, Xianzhilou will attend ICMCM Fair in Hongkong
Xianzhilou
Xianzhilou attended Interherb 2008 (Qingdao) Exhibition
The students of  Biological Engineering Institute of Fuzhou University visit  Xianzhilou on May 13th
Fair Report :The 103Th China Import and Export Fair
April 2008, Xianzhilou Group won the Title “ National R&D Center for Edible Fungi Processing”
Lucidenic acid reduces binding activities of NF-{kappa}B and AP-1.
Lucidenic acid inhibits activities of hepatoma cells
  

 Carcinogenesis. [Epub ahead of print]

Lucidenic acid inhibits PMA-induced invasion of human hepatoma cells through inactivating MAPK/ERK signal transduction pathway and reducing binding activities of NF-{kappa}B and AP-1.

Weng CJ, Chau CF, Hsieh YS, Yang SF, Yen GC.
Department of Food Science and Biotechnology, National Chung Hsing University, Taichung, Taiwan.
Ganoderma lucidum has been reported to be associated with suppressed motility, invasion and metastasis of several types of cancers, but its mechanism of action remains unclear. In our previous study, lucidenic acids A, B, C and N were isolated from a new strain of G. lucidum and all of them were found to have potential anti-invasive activity on phorbol-12-myristate-13-acetate (PMA)-induced HepG(2) cells by suppressing the matrix metalloproteinase (MMP)-9 activity.
Here, the lucidenic acid B was used to explore its mechanisms underlying MMP-9 expression of HepG(2) cells. The results showed that the lucidenic acid B suppressed PMA-induced MMP-9 activity in a dose-dependent transcriptional level. The suppression of PMA-induced MMP-9 expression of HepG(2) cells by lucidenic acid B was through inactivating phosphorylation of ERK1/2. The treatment of MEK inhibitors (PD98059 and U0126) and lucidenic acid B to HepG(2) cells could result in a synergistic reduction on the MMP-9 expression along with an inhibition on cell invasion. Moreover, lucidenic acid B also strongly inhibited PMA-stimulated nuclear factor-kappa B (NF-kappaB) and activator protein-1 (AP-1) DNA binding activities of HepG(2) cells in dose-dependent manners. A dose-dependent inhibition on protein levels of NF-kappaB, c-Jun and c-Fos in nuclear by lucidenic acid B treatment was further observed.
In conclusion, we demonstrated that the anti-invasive effects of the lucidenic acid B on the PMA-induced HepG(2) cells might be through inhibiting the phosphorylation of ERK1/2 and reducing AP-1 and NF-kappaB DNA binding activities, leading to down-regulation of MMP-9 expression.
PMID: 18024477 [PubMed - as supplied by publisher]

 
Fujian Xianzhilou Biological Science & Technology Co., Ltd.
Address31 Building, Juyuanzhou Industrial Zone, No. 618 Jinshan Road, Fuzhou, Fujian Province, China Zip Code: 350002
Tel.: 86-591-83053398
   Fax: 86-591-83053396